Hepatic (Liver) and Metabolic Capabilities

At Ichor Research, we understand the unique capabilities required to execute complicated and complex liver and metabolic studies. With experience running studies targeting various stages of liver fibrosis and metabolic impairment, with varying etiologies, we can support your early and late phase clinical trials.

GLP-1 study experience

Our team has expertise in conducting studies with GLP-1 medications, with the capabilities to ensure IP storage and administration compliance as well as knowledge and know-how to properly oversee the safety of trial participants.

MRI

Local and ready to scan imaging partners with MRI-PDFF and CT1.

Biopsy

Ichor can include both screening and ongoing liver biopsy services as needed for clinical trials, with or without ultrasound guidance as required per protocol.

Fibroscan

With 4 certified operators, we provide onsite Fibroscan. Additinally, our team has an IRB approved Fibroscan prescreening consent as well as capabilities to support ongoing Fibroscan throughout the course of your clinical trial.

Our Study Experience

Therapeutic Indications:

MASH/NASH (F0-F4)
Alcoholic Liver Disease (ALD)
Metabolic Disorders (patients with comorbid disorders including diabetes and impaired fasting glucose, metabolic syndrome).

Our clinical trial investigators and staff have supported studies ranging from F0-F1 fibrosis scores, with and without biopsy, and utilizing additional biomarker and imaging capabilities to support in accurate diagnosis and qualification of participants.

If your team would like to learn more about our ability to support your upcoming study, please complete the form below.